Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name (Ascending) Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
62756-0102-60 62756-0102 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 July 31, 2023 No Longer Used
62756-0219-60 62756-0219 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 July 31, 2023 No Longer Used
62756-0321-60 62756-0321 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 July 31, 2023 No Longer Used
62756-0438-60 62756-0438 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 No Longer Used
62756-0533-60 62756-0533 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 July 31, 2023 No Longer Used
62756-0614-60 62756-0614 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 July 31, 2023 No Longer Used
62756-0746-60 62756-0746 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 July 31, 2023 No Longer Used
62756-0974-60 62756-0974 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 July 31, 2023 No Longer Used
64842-0727-09 64842-0727 CEDAZURIDINE and DECITABINE INQOVI 100.0 mg/1, 35.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog + CDA Inhibitor Oral Aug. 25, 2020 In Use
00310-0482-30 00310-0482 Gefitinib IRESSA 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 13, 2015 In Use
00310-0482-93 00310-0482 Gefitinib IRESSA 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 25, 2016 Aug. 31, 2019 In Use
55150-0355-01 55150-0355 IRINOTECAN HYDROCHLORIDE IRINOTECAN HYDROCHLORIDE 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous April 11, 2022 In Use
55150-0352-01 55150-0352 IRINOTECAN HYDROCHLORIDE IRINOTECAN HYDROCHLORIDE 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 11, 2020 In Use
55150-0353-01 55150-0353 IRINOTECAN HYDROCHLORIDE IRINOTECAN HYDROCHLORIDE 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 11, 2020 In Use
55150-0354-01 55150-0354 IRINOTECAN HYDROCHLORIDE IRINOTECAN HYDROCHLORIDE 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 11, 2020 In Use
59651-0631-03 59651-0631 ISOTRETINOIN ISOTRETINOIN 10.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Jan. 29, 2024 In Use
59651-0632-03 59651-0632 ISOTRETINOIN ISOTRETINOIN 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Jan. 29, 2024 In Use
59651-0633-03 59651-0633 ISOTRETINOIN ISOTRETINOIN 25.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Jan. 29, 2024 In Use
59651-0634-03 59651-0634 ISOTRETINOIN ISOTRETINOIN 30.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Jan. 29, 2024 In Use
59651-0635-03 59651-0635 ISOTRETINOIN ISOTRETINOIN 35.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Jan. 29, 2024 In Use
59651-0636-03 59651-0636 ISOTRETINOIN ISOTRETINOIN 40.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Jan. 29, 2024 In Use
00310-4715-11 00310-4715 IV Solution Stabilizer for Lumoxiti IV Solution Stabilizer for Lumoxiti 6.5 mg/mL Ancillary Therapy Excipient Intravenous Oct. 24, 2018 In Use
63539-0688-03 63539-0688 palbociclib Ibrance 125.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 30, 2020 In Use
63539-0284-03 63539-0284 palbociclib Ibrance 75.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 30, 2020 In Use
63539-0486-03 63539-0486 palbociclib Ibrance 100.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 30, 2020 In Use
00069-0284-03 00069-0284 Palbociclib Ibrance 75.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 30, 2020 In Use
00069-0187-21 00069-0187 Palbociclib Ibrance 75.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral Feb. 3, 2015 In Use
00069-0188-21 00069-0188 Palbociclib Ibrance 100.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral Feb. 3, 2015 In Use
00069-0189-21 00069-0189 Palbociclib Ibrance 125.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral Feb. 3, 2015 In Use
63539-0189-11 63539-0189 Palbociclib Ibrance 125.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral Feb. 3, 2015 In Use
00069-0688-03 00069-0688 palbociclib Ibrance 125.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 30, 2020 In Use
00069-0486-03 00069-0486 Palbociclib Ibrance 100.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 30, 2020 In Use
76189-0533-30 76189-0533 Ponatinib Hydrochloride Iclusig 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral April 22, 2015 July 26, 2020 No Longer Used
76189-0534-30 76189-0534 Ponatinib Hydrochloride Iclusig 45.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec. 14, 2012 July 26, 2020 No Longer Used
76189-0534-90 76189-0534 Ponatinib Hydrochloride Iclusig 45.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec. 14, 2012 July 26, 2020 No Longer Used
76189-0535-30 76189-0535 Ponatinib Hydrochloride Iclusig 15.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec. 14, 2012 July 26, 2020 No Longer Used
76189-0535-60 76189-0535 Ponatinib Hydrochloride Iclusig 15.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec. 14, 2012 July 26, 2020 No Longer Used
76189-0535-80 76189-0535 Ponatinib Hydrochloride Iclusig 15.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec. 14, 2012 July 26, 2020 No Longer Used
63020-0536-30 63020-0536 ponatinib hydrochloride Iclusig 10.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 11, 2021 In Use
00013-2526-86 00013-2526 Idarubicin Hydrochloride Idamycin Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Sept. 27, 1990 June 1, 2010 No Longer Used
00013-2200-01 00013-2200 Idarubicin Hydrochloride Idamycin PFS Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Feb. 17, 1997 June 1, 2010 No Longer Used
00013-2202-01 00013-2202 Idarubicin Hydrochloride Idamycin PFS Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Feb. 17, 1997 June 1, 2010 No Longer Used
00013-2586-91 00013-2586 Idarubicin Hydrochloride Idamycin PFS 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Feb. 17, 1997 In Use
00013-2586-10 00013-2586 Idarubicin Hydrochloride Idamycin PFS 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous March 11, 2024 In Use
00013-2596-91 00013-2596 Idarubicin Hydrochloride Idamycin PFS 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Feb. 17, 1997 In Use
00013-2596-20 00013-2596 Idarubicin Hydrochloride Idamycin PFS 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous March 11, 2024 In Use
00013-2201-01 00013-2201 Idarubicin Hydrochloride Idamycin PFS Chemotherapy Antitumor Antibiotic Anthracycline Feb. 17, 1997 June 1, 2010 No Longer Used
00013-2576-91 00013-2576 Idarubicin Hydrochloride Idamycin PFS 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Feb. 17, 1997 In Use
55390-0215-01 55390-0215 Idarubicin Hydrochloride Idarubicin Hydrochloride Chemotherapy Antitumor Antibiotic Anthracycline Intravenous May 15, 2007 Sept. 30, 2011 No Longer Used
55390-0216-01 55390-0216 Idarubicin Hydrochloride Idarubicin Hydrochloride Chemotherapy Antitumor Antibiotic Anthracycline Intravenous May 15, 2007 Sept. 30, 2011 No Longer Used

Found 10,000 results in 8 millisecondsExport these results